Abstract:Studies comparing antibody responses against SARS-CoV-2 between children and adults show conflicting results in blood and are limited in the mucosa. Furthermore, as the results of studies comparing systemic and salivary immune responses are inconsistent, it is unclear whether determination of salivary antibodies against SARS-CoV-2 could be a non-invasive approach to evaluate the humoral immune response. In this work, by studying and comparing systemic and salivary IgG antibody responses in vaccinated adults, we observed that the salivary immune response against SARS-CoV-2 in vaccinated adults largely reflects that observed at systemic levels. Higher salivary and systemic antibody concentrations were observed in adults who had schedules that included mRNA-based vaccines, a greater number of exposures, a shorter interval time between last exposure and saliva collection and had been exposed to SARS-CoV-2. Detection of salivary antibodies was associated with schedules that included mRNA-based vaccines, time between last exposure and sample collection, and systemic antibody concentrations. This suggests that salivary antibody detection might be compromised in subjects with lower systemic antibody levels. Comparison of salivary antibody levels between vaccinated children and adults showed a stronger salivary antibody response against SARS-CoV-2 in vaccinated children. This also remained when antibody levels were compared between children and adults who had similar vaccination schedules or the same number of exposures or interval time between last exposure and saliva collection. A multivariable linear regression analysis confirmed these results showing that age, symptomatic exposure, number of vaccine doses and schedules that included mRNA-based vaccines associated with salivary anti-SARS-CoV-2 IgG antibody levels. Determination of salivary antibodies against SARS-CoV-2 could be a non-invasive approach to evaluate the short-term immune response in children and adults with multiple exposures, especially in settings where blood sampling cannot be fulfilled. The higher levels of salivary anti-SARS-CoV-2 IgG antibodies observed in children align with studies reporting stronger systemic antibody responses in children, suggesting their adaptive immune responses might be more efficient both locally and systemically. Further studies are required to characterize the salivary microenvironment for a better understanding of the difference observed in the local humoral immune response between children and adults.

SARS-CoV-2–specific mucosal immune response in vaccinated versus infected children

Salivary IgG antibody response against SARS-CoV-2 differs between vaccinated children and adults

COVID-19 mRNA vaccines induce robust levels of IgG but limited amounts of IgA within the oronasopharynx of young children

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva

Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal Cohort

Comparison of levels of nasal, salivary, and plasma antibody to SARS-CoV-2 during natural infection and after vaccination

Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection

SARS-CoV-2-Specific Immune Responses in Vaccination and Infection during the Pandemic in 2020–2022

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

Salivary immune responses after COVID-19 vaccination

Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination

The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines

The Immunological Profile of SARS-CoV-2 Infection in Children Is Linked to Clinical Severity and Age

Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination

Humoral and cellular immune responses in vaccinated and unvaccinated children following SARS‐CoV‐2 Omicron infection

Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

Subclinical SARS-CoV-2 Infections and Endemic Human Coronavirus Immunity Shape SARS-CoV-2 Saliva Antibody Responses

Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial

Serum and Salivary IgG and IgA Response After COVID-19 mRNA Vaccination

Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants in Children With Coronavirus Disease 2019, Multisystem Inflammatory Syndrome in Children, and After Two Doses of BNT162b2 Vaccination